The patient screening component of the newly launched Lung Cancer Master Protocol trial is expected to translate into significant cost-savings that is making the collaborative, multiple-drug “basket” design attractive to industry.
Lung-MAP, which formally launched June 16, has a multiple arm set-up allowing several drugs to be tested simultaneously across a larger pool of patients who will be screened for a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?